Zhiqiang Qin
Concepts (386)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Herpesvirus 8, Human | 46 | 2025 | 97 | 20.560 |
Why?
| Sarcoma, Kaposi | 28 | 2025 | 75 | 12.470 |
Why?
| Lymphoma, Primary Effusion | 13 | 2025 | 20 | 6.560 |
Why?
| Virus Activation | 9 | 2025 | 37 | 4.220 |
Why?
| Coinfection | 6 | 2025 | 41 | 3.820 |
Why?
| Endogenous Retroviruses | 4 | 2024 | 7 | 3.290 |
Why?
| Host-Pathogen Interactions | 8 | 2020 | 135 | 2.230 |
Why?
| Oncogenic Viruses | 4 | 2021 | 15 | 2.080 |
Why?
| MicroRNAs | 12 | 2020 | 344 | 2.020 |
Why?
| Pyridines | 5 | 2018 | 131 | 1.960 |
Why?
| Mouth | 4 | 2020 | 32 | 1.890 |
Why?
| Herpesviridae Infections | 7 | 2025 | 54 | 1.860 |
Why?
| Gene Expression Regulation, Neoplastic | 11 | 2021 | 833 | 1.830 |
Why?
| Viral Proteins | 8 | 2021 | 153 | 1.810 |
Why?
| Virus Latency | 9 | 2025 | 52 | 1.790 |
Why?
| Cell Line, Tumor | 19 | 2025 | 1398 | 1.770 |
Why?
| Humans | 82 | 2025 | 50503 | 1.750 |
Why?
| Phosphotransferases (Alcohol Group Acceptor) | 5 | 2018 | 23 | 1.750 |
Why?
| HIV Infections | 6 | 2020 | 352 | 1.700 |
Why?
| Gene Expression Regulation, Viral | 9 | 2020 | 47 | 1.670 |
Why?
| Lung Neoplasms | 6 | 2022 | 601 | 1.660 |
Why?
| Adamantane | 4 | 2018 | 24 | 1.610 |
Why?
| Signal Transduction | 14 | 2022 | 1624 | 1.600 |
Why?
| Gene Expression Regulation | 7 | 2019 | 955 | 1.560 |
Why?
| Ceramides | 4 | 2020 | 31 | 1.540 |
Why?
| Carcinoma, Non-Small-Cell Lung | 5 | 2021 | 154 | 1.520 |
Why?
| Schistosomiasis japonica | 2 | 2023 | 2 | 1.510 |
Why?
| Apoptosis | 16 | 2025 | 1097 | 1.480 |
Why?
| Autoantibodies | 4 | 2023 | 117 | 1.400 |
Why?
| Neoplasms | 3 | 2024 | 1251 | 1.330 |
Why?
| Cell Proliferation | 14 | 2025 | 985 | 1.300 |
Why?
| Amino Acid Transport System y+ | 3 | 2015 | 3 | 1.290 |
Why?
| Antiviral Agents | 2 | 2021 | 170 | 1.260 |
Why?
| Papillomavirus Infections | 2 | 2024 | 168 | 1.240 |
Why?
| Lymphoma | 3 | 2019 | 67 | 1.230 |
Why?
| Animals | 31 | 2025 | 13124 | 1.230 |
Why?
| Proto-Oncogene Proteins c-met | 3 | 2017 | 18 | 1.200 |
Why?
| Uterine Cervical Neoplasms | 2 | 2024 | 276 | 1.180 |
Why?
| Xenograft Model Antitumor Assays | 8 | 2025 | 212 | 1.140 |
Why?
| Interleukin-1 | 2 | 2025 | 105 | 1.110 |
Why?
| Mice | 19 | 2025 | 5687 | 1.070 |
Why?
| Bacterial Proteins | 3 | 2020 | 367 | 1.070 |
Why?
| Gene Expression Profiling | 8 | 2025 | 1025 | 0.990 |
Why?
| Epstein-Barr Virus Infections | 3 | 2022 | 30 | 0.970 |
Why?
| Cell Transformation, Viral | 2 | 2016 | 25 | 0.940 |
Why?
| Antineoplastic Agents | 3 | 2025 | 1172 | 0.930 |
Why?
| Interleukin-10 | 2 | 2018 | 84 | 0.930 |
Why?
| Induced Pluripotent Stem Cells | 1 | 2025 | 41 | 0.930 |
Why?
| Biological Therapy | 1 | 2024 | 16 | 0.900 |
Why?
| Histamine | 2 | 2023 | 25 | 0.890 |
Why?
| Oropharyngeal Neoplasms | 1 | 2024 | 19 | 0.880 |
Why?
| Anus Neoplasms | 1 | 2024 | 24 | 0.880 |
Why?
| Eukaryotic Initiation Factor-4G | 2 | 2021 | 3 | 0.870 |
Why?
| Virus Replication | 6 | 2025 | 139 | 0.860 |
Why?
| Virus Diseases | 1 | 2024 | 42 | 0.860 |
Why?
| Echinomycin | 1 | 2023 | 6 | 0.850 |
Why?
| Penile Neoplasms | 1 | 2024 | 44 | 0.850 |
Why?
| Cough | 1 | 2023 | 54 | 0.850 |
Why?
| Interferon Type I | 1 | 2023 | 24 | 0.830 |
Why?
| Herpesviridae | 2 | 2022 | 17 | 0.830 |
Why?
| Endothelial Cells | 5 | 2024 | 258 | 0.810 |
Why?
| Nuclear Proteins | 5 | 2023 | 238 | 0.800 |
Why?
| Porphyromonas gingivalis | 2 | 2020 | 14 | 0.800 |
Why?
| Mycoses | 1 | 2023 | 155 | 0.800 |
Why?
| Human Umbilical Vein Endothelial Cells | 4 | 2019 | 90 | 0.800 |
Why?
| Tumor Microenvironment | 3 | 2025 | 222 | 0.770 |
Why?
| Small Cell Lung Carcinoma | 1 | 2022 | 28 | 0.760 |
Why?
| Sphingolipids | 2 | 2020 | 15 | 0.750 |
Why?
| Schistosoma japonicum | 2 | 2018 | 2 | 0.750 |
Why?
| RNA, Viral | 4 | 2022 | 107 | 0.750 |
Why?
| Matrix Metalloproteinase 9 | 2 | 2018 | 88 | 0.730 |
Why?
| Cell Line | 9 | 2021 | 988 | 0.710 |
Why?
| Antigens, Viral | 4 | 2016 | 42 | 0.690 |
Why?
| Brain Stem Neoplasms | 1 | 2020 | 4 | 0.690 |
Why?
| Antigens, Bacterial | 1 | 2020 | 51 | 0.690 |
Why?
| Cell Survival | 6 | 2025 | 589 | 0.690 |
Why?
| Drug Resistance, Neoplasm | 3 | 2019 | 316 | 0.690 |
Why?
| Gene Regulatory Networks | 1 | 2021 | 106 | 0.680 |
Why?
| Staphylococcus epidermidis | 2 | 2012 | 13 | 0.670 |
Why?
| Antineoplastic Agents, Phytogenic | 1 | 2020 | 66 | 0.670 |
Why?
| Tumor Virus Infections | 1 | 2019 | 47 | 0.670 |
Why?
| Programmed Cell Death 1 Ligand 2 Protein | 1 | 2019 | 3 | 0.660 |
Why?
| Cells, Cultured | 6 | 2025 | 1571 | 0.650 |
Why?
| Hepatocyte Growth Factor | 2 | 2016 | 10 | 0.650 |
Why?
| Programmed Cell Death 1 Receptor | 1 | 2019 | 39 | 0.640 |
Why?
| Helminth Proteins | 1 | 2018 | 2 | 0.620 |
Why?
| Antigens, Helminth | 1 | 2018 | 4 | 0.620 |
Why?
| Antibodies, Antinuclear | 1 | 2018 | 14 | 0.620 |
Why?
| Antibodies, Protozoan | 1 | 2018 | 12 | 0.620 |
Why?
| Endothelium, Vascular | 3 | 2016 | 251 | 0.610 |
Why?
| 4-Butyrolactone | 1 | 2018 | 5 | 0.610 |
Why?
| Interleukin-12 | 1 | 2018 | 29 | 0.610 |
Why?
| Mycobacterium tuberculosis | 1 | 2020 | 266 | 0.610 |
Why?
| Fibroblasts | 4 | 2016 | 336 | 0.610 |
Why?
| Interleukin-17 | 1 | 2018 | 37 | 0.610 |
Why?
| Quorum Sensing | 1 | 2018 | 9 | 0.600 |
Why?
| Male | 21 | 2024 | 25907 | 0.600 |
Why?
| Tumor Cells, Cultured | 5 | 2020 | 457 | 0.590 |
Why?
| Hyaluronic Acid | 2 | 2015 | 34 | 0.590 |
Why?
| Transcriptional Activation | 1 | 2018 | 119 | 0.580 |
Why?
| Up-Regulation | 7 | 2020 | 446 | 0.580 |
Why?
| Quinolones | 1 | 2018 | 41 | 0.580 |
Why?
| Papillomavirus E7 Proteins | 1 | 2017 | 31 | 0.570 |
Why?
| Middle Aged | 14 | 2023 | 12611 | 0.550 |
Why?
| Oncogene Proteins, Viral | 1 | 2017 | 52 | 0.550 |
Why?
| Urinary Bladder Neoplasms | 1 | 2018 | 158 | 0.550 |
Why?
| Mice, SCID | 5 | 2020 | 178 | 0.550 |
Why?
| Keratin-1 | 2 | 2013 | 2 | 0.540 |
Why?
| Herpesvirus 4, Human | 3 | 2022 | 37 | 0.540 |
Why?
| Trans-Activators | 2 | 2020 | 134 | 0.530 |
Why?
| Lipid Metabolism | 1 | 2017 | 175 | 0.530 |
Why?
| Heme Oxygenase-1 | 1 | 2016 | 18 | 0.520 |
Why?
| Epithelial-Mesenchymal Transition | 5 | 2019 | 51 | 0.510 |
Why?
| Repressor Proteins | 1 | 2017 | 148 | 0.510 |
Why?
| ADAM Proteins | 1 | 2016 | 20 | 0.510 |
Why?
| Female | 18 | 2024 | 27081 | 0.500 |
Why?
| Histocompatibility Antigens Class I | 2 | 2013 | 46 | 0.500 |
Why?
| Cell Transformation, Neoplastic | 4 | 2023 | 181 | 0.490 |
Why?
| Piperidines | 1 | 2015 | 99 | 0.480 |
Why?
| Acquired Immunodeficiency Syndrome | 1 | 2015 | 53 | 0.470 |
Why?
| Teichoic Acids | 1 | 2014 | 7 | 0.460 |
Why?
| Virus Internalization | 1 | 2014 | 17 | 0.460 |
Why?
| Lymphoma, AIDS-Related | 1 | 2014 | 16 | 0.460 |
Why?
| Cell Cycle Checkpoints | 3 | 2020 | 29 | 0.440 |
Why?
| Reverse Transcriptase Polymerase Chain Reaction | 4 | 2017 | 572 | 0.430 |
Why?
| Mice, Inbred NOD | 4 | 2020 | 91 | 0.430 |
Why?
| Isoantigens | 1 | 2013 | 10 | 0.430 |
Why?
| eIF-2 Kinase | 1 | 2013 | 10 | 0.430 |
Why?
| Lipopolysaccharides | 1 | 2014 | 197 | 0.420 |
Why?
| Graft Rejection | 2 | 2013 | 172 | 0.420 |
Why?
| Dual Specificity Phosphatase 1 | 1 | 2012 | 9 | 0.410 |
Why?
| Biofilms | 2 | 2012 | 182 | 0.410 |
Why?
| Disease Models, Animal | 4 | 2025 | 1436 | 0.400 |
Why?
| RNA-Binding Proteins | 1 | 2013 | 118 | 0.390 |
Why?
| Adaptor Proteins, Signal Transducing | 1 | 2013 | 198 | 0.390 |
Why?
| Catheters, Indwelling | 1 | 2012 | 57 | 0.390 |
Why?
| Mice, Nude | 5 | 2020 | 248 | 0.390 |
Why?
| Receptors, Histamine | 2 | 2023 | 7 | 0.380 |
Why?
| Neoplasm Invasiveness | 5 | 2019 | 269 | 0.380 |
Why?
| Kidney Transplantation | 2 | 2013 | 189 | 0.380 |
Why?
| Adult | 10 | 2020 | 13577 | 0.380 |
Why?
| Autoantigens | 2 | 2023 | 48 | 0.370 |
Why?
| Protein Kinase Inhibitors | 2 | 2018 | 204 | 0.370 |
Why?
| NM23 Nucleoside Diphosphate Kinases | 1 | 2011 | 4 | 0.370 |
Why?
| Young Adult | 5 | 2020 | 4102 | 0.360 |
Why?
| Cell Cycle Proteins | 2 | 2023 | 161 | 0.360 |
Why?
| Gene Expression Regulation, Bacterial | 1 | 2012 | 188 | 0.360 |
Why?
| Mitogen-Activated Protein Kinases | 2 | 2011 | 155 | 0.350 |
Why?
| Monocytes | 2 | 2017 | 127 | 0.350 |
Why?
| Interferons | 2 | 2023 | 38 | 0.340 |
Why?
| Macrophages | 2 | 2010 | 364 | 0.340 |
Why?
| CCAAT-Enhancer-Binding Protein-beta | 1 | 2010 | 4 | 0.340 |
Why?
| Cell Movement | 5 | 2020 | 247 | 0.340 |
Why?
| High-Throughput Screening Assays | 2 | 2020 | 35 | 0.340 |
Why?
| HSP90 Heat-Shock Proteins | 1 | 2010 | 51 | 0.340 |
Why?
| RNA Interference | 5 | 2016 | 178 | 0.330 |
Why?
| Immunoblotting | 3 | 2015 | 115 | 0.330 |
Why?
| Heart Transplantation | 2 | 2013 | 363 | 0.330 |
Why?
| Coronary Artery Disease | 1 | 2013 | 278 | 0.320 |
Why?
| Blotting, Western | 3 | 2017 | 578 | 0.320 |
Why?
| Disease Progression | 5 | 2021 | 829 | 0.320 |
Why?
| Down-Regulation | 3 | 2017 | 340 | 0.310 |
Why?
| Interleukin-6 | 1 | 2010 | 261 | 0.300 |
Why?
| RNA, Messenger | 4 | 2017 | 1089 | 0.300 |
Why?
| Staphylococcus aureus | 3 | 2020 | 321 | 0.300 |
Why?
| Aged | 6 | 2020 | 9741 | 0.290 |
Why?
| Carcinoma, Renal Cell | 2 | 2020 | 101 | 0.290 |
Why?
| Fluorescent Antibody Technique | 3 | 2015 | 104 | 0.290 |
Why?
| CD8-Positive T-Lymphocytes | 3 | 2024 | 125 | 0.290 |
Why?
| Hypertension | 2 | 2024 | 544 | 0.290 |
Why?
| HIV | 2 | 2019 | 25 | 0.290 |
Why?
| RNA, Small Interfering | 3 | 2016 | 208 | 0.280 |
Why?
| Real-Time Polymerase Chain Reaction | 3 | 2017 | 181 | 0.280 |
Why?
| Transcription Factors | 2 | 2023 | 565 | 0.280 |
Why?
| Protein Kinases | 1 | 2006 | 71 | 0.260 |
Why?
| Virulence Factors | 2 | 2020 | 78 | 0.260 |
Why?
| Postoperative Complications | 1 | 2013 | 1033 | 0.260 |
Why?
| Schistosomiasis | 1 | 2025 | 4 | 0.250 |
Why?
| Disease Eradication | 1 | 2025 | 2 | 0.250 |
Why?
| Structure-Activity Relationship | 3 | 2020 | 395 | 0.250 |
Why?
| Oxidative Stress | 1 | 2010 | 772 | 0.240 |
Why?
| International Cooperation | 1 | 2025 | 47 | 0.240 |
Why?
| Interferon-gamma | 2 | 2023 | 177 | 0.240 |
Why?
| MAP Kinase Signaling System | 2 | 2015 | 117 | 0.230 |
Why?
| Oncogene Proteins | 1 | 2024 | 16 | 0.230 |
Why?
| Endothelium, Lymphatic | 1 | 2024 | 12 | 0.230 |
Why?
| Molecular Structure | 2 | 2020 | 296 | 0.220 |
Why?
| Oligonucleotide Array Sequence Analysis | 2 | 2015 | 405 | 0.220 |
Why?
| Phosphorylation | 2 | 2017 | 525 | 0.220 |
Why?
| DNA Damage | 2 | 2016 | 301 | 0.220 |
Why?
| Immunocompromised Host | 2 | 2015 | 119 | 0.220 |
Why?
| Cytokines | 2 | 2017 | 606 | 0.220 |
Why?
| Immunohistochemistry | 2 | 2021 | 957 | 0.220 |
Why?
| Jumonji Domain-Containing Histone Demethylases | 1 | 2023 | 17 | 0.210 |
Why?
| Dose-Response Relationship, Drug | 3 | 2020 | 1372 | 0.210 |
Why?
| Polymerase Chain Reaction | 3 | 2015 | 449 | 0.210 |
Why?
| Interferon-alpha | 1 | 2023 | 47 | 0.210 |
Why?
| Amino Acid Sequence | 3 | 2017 | 574 | 0.210 |
Why?
| DNA Repair | 1 | 2024 | 188 | 0.200 |
Why?
| Transfection | 3 | 2014 | 356 | 0.200 |
Why?
| Ultrasonography, Interventional | 1 | 2023 | 137 | 0.200 |
Why?
| Histone Deacetylase Inhibitors | 1 | 2023 | 56 | 0.200 |
Why?
| Tubercidin | 1 | 2022 | 3 | 0.200 |
Why?
| Amaryllidaceae Alkaloids | 1 | 2022 | 3 | 0.200 |
Why?
| Phenanthridines | 1 | 2022 | 4 | 0.200 |
Why?
| Gene Expression | 1 | 2025 | 610 | 0.200 |
Why?
| Transaminases | 1 | 2022 | 11 | 0.200 |
Why?
| Adenosine Monophosphate | 1 | 2022 | 15 | 0.200 |
Why?
| Cell Cycle | 1 | 2023 | 226 | 0.190 |
Why?
| Alanine | 1 | 2022 | 43 | 0.190 |
Why?
| Lymph Nodes | 1 | 2023 | 257 | 0.190 |
Why?
| Benzamidines | 1 | 2021 | 5 | 0.190 |
Why?
| Azithromycin | 1 | 2021 | 25 | 0.190 |
Why?
| Severity of Illness Index | 1 | 2025 | 978 | 0.190 |
Why?
| HEK293 Cells | 2 | 2019 | 213 | 0.190 |
Why?
| Guanidines | 1 | 2021 | 29 | 0.190 |
Why?
| Neoplasm Transplantation | 3 | 2019 | 86 | 0.180 |
Why?
| Isoantibodies | 2 | 2013 | 29 | 0.180 |
Why?
| Immune Evasion | 1 | 2021 | 11 | 0.180 |
Why?
| Lymphoma, Non-Hodgkin | 1 | 2021 | 55 | 0.180 |
Why?
| Ubiquitin | 1 | 2020 | 45 | 0.180 |
Why?
| Bacteroidaceae Infections | 1 | 2020 | 4 | 0.180 |
Why?
| Immunotherapy | 1 | 2022 | 235 | 0.170 |
Why?
| Enzyme-Linked Immunosorbent Assay | 3 | 2015 | 234 | 0.170 |
Why?
| Drug Screening Assays, Antitumor | 1 | 2020 | 131 | 0.170 |
Why?
| Survival Rate | 2 | 2021 | 909 | 0.170 |
Why?
| Tumor Escape | 1 | 2019 | 17 | 0.160 |
Why?
| Drug Evaluation, Preclinical | 1 | 2019 | 145 | 0.160 |
Why?
| Interleukin-1beta | 1 | 2019 | 72 | 0.160 |
Why?
| Homeodomain Proteins | 1 | 2019 | 79 | 0.160 |
Why?
| Kidney Neoplasms | 1 | 2020 | 174 | 0.160 |
Why?
| Bacterial Load | 1 | 2018 | 12 | 0.150 |
Why?
| Autoimmunity | 1 | 2018 | 34 | 0.150 |
Why?
| Transplantation, Heterologous | 2 | 2019 | 75 | 0.150 |
Why?
| HIV-1 | 1 | 2018 | 54 | 0.150 |
Why?
| Prognosis | 4 | 2021 | 1978 | 0.150 |
Why?
| Neovascularization, Pathologic | 1 | 2019 | 155 | 0.150 |
Why?
| Pseudomonas Infections | 1 | 2018 | 48 | 0.150 |
Why?
| Cell Growth Processes | 1 | 2018 | 22 | 0.150 |
Why?
| Pseudomonas aeruginosa | 1 | 2018 | 72 | 0.150 |
Why?
| Virulence | 1 | 2018 | 168 | 0.140 |
Why?
| Microscopy, Electron | 1 | 2017 | 77 | 0.140 |
Why?
| Pandemics | 1 | 2022 | 563 | 0.140 |
Why?
| Annexin A5 | 1 | 2017 | 14 | 0.140 |
Why?
| Sphingosine | 2 | 2015 | 28 | 0.140 |
Why?
| Random Allocation | 1 | 2018 | 289 | 0.140 |
Why?
| Lysophospholipids | 2 | 2015 | 44 | 0.140 |
Why?
| Matrix Metalloproteinase 2 | 1 | 2017 | 59 | 0.140 |
Why?
| CD4-Positive T-Lymphocytes | 1 | 2018 | 158 | 0.140 |
Why?
| Toll-Like Receptor 2 | 1 | 2017 | 24 | 0.140 |
Why?
| Staphylococcal Infections | 2 | 2012 | 267 | 0.140 |
Why?
| Exons | 1 | 2017 | 93 | 0.140 |
Why?
| Exoribonucleases | 1 | 2016 | 2 | 0.130 |
Why?
| Exonucleases | 1 | 2016 | 5 | 0.130 |
Why?
| Toll-Like Receptor 4 | 1 | 2017 | 52 | 0.130 |
Why?
| Pleural Effusion | 1 | 2017 | 38 | 0.130 |
Why?
| Ubiquitins | 1 | 2016 | 39 | 0.130 |
Why?
| Lung | 1 | 2020 | 504 | 0.130 |
Why?
| Tuberculosis, Pulmonary | 1 | 2017 | 105 | 0.130 |
Why?
| Receptors, Cell Surface | 1 | 2017 | 116 | 0.130 |
Why?
| Protoporphyrins | 1 | 2016 | 5 | 0.130 |
Why?
| Metalloporphyrins | 1 | 2016 | 6 | 0.130 |
Why?
| Autophagy | 1 | 2017 | 170 | 0.130 |
Why?
| Molluscacides | 1 | 2015 | 1 | 0.130 |
Why?
| Salicylanilides | 1 | 2015 | 1 | 0.130 |
Why?
| Gastropoda | 1 | 2015 | 2 | 0.130 |
Why?
| Comet Assay | 1 | 2015 | 10 | 0.130 |
Why?
| Anthelmintics | 1 | 2015 | 8 | 0.130 |
Why?
| Base Sequence | 1 | 2017 | 639 | 0.130 |
Why?
| Membrane Proteins | 1 | 2018 | 332 | 0.130 |
Why?
| High-Throughput Nucleotide Sequencing | 1 | 2017 | 169 | 0.130 |
Why?
| Necrosis | 1 | 2016 | 174 | 0.120 |
Why?
| Oxidoreductases | 1 | 2015 | 59 | 0.120 |
Why?
| Protein Binding | 3 | 2020 | 654 | 0.120 |
Why?
| Nerve Tissue Proteins | 1 | 2017 | 194 | 0.120 |
Why?
| Cohort Studies | 1 | 2019 | 1452 | 0.120 |
Why?
| Transcriptome | 1 | 2017 | 313 | 0.120 |
Why?
| Pyrazoles | 1 | 2015 | 111 | 0.120 |
Why?
| Mice, Inbred BALB C | 3 | 2020 | 296 | 0.120 |
Why?
| Glutamates | 1 | 2014 | 22 | 0.110 |
Why?
| Cystine | 1 | 2014 | 11 | 0.110 |
Why?
| Lymphocytes | 2 | 2017 | 149 | 0.110 |
Why?
| Glucuronosyltransferase | 1 | 2015 | 122 | 0.110 |
Why?
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2019 | 1000 | 0.110 |
Why?
| Transplantation | 1 | 2013 | 15 | 0.110 |
Why?
| Immunoprecipitation | 1 | 2013 | 59 | 0.110 |
Why?
| HLA Antigens | 1 | 2013 | 52 | 0.100 |
Why?
| Sodium Chloride, Dietary | 2 | 2024 | 31 | 0.100 |
Why?
| Flow Cytometry | 1 | 2015 | 474 | 0.100 |
Why?
| Sodium | 2 | 2024 | 92 | 0.100 |
Why?
| Molecular Targeted Therapy | 1 | 2013 | 123 | 0.100 |
Why?
| NF-kappa B | 1 | 2014 | 315 | 0.100 |
Why?
| Bacteriolysis | 1 | 2012 | 2 | 0.100 |
Why?
| Bacterial Adhesion | 1 | 2012 | 15 | 0.100 |
Why?
| Polymorphism, Genetic | 2 | 2013 | 180 | 0.100 |
Why?
| RNA, Bacterial | 1 | 2012 | 58 | 0.100 |
Why?
| Reactive Oxygen Species | 1 | 2014 | 409 | 0.100 |
Why?
| Mouth Neoplasms | 1 | 2011 | 20 | 0.100 |
Why?
| DNA, Bacterial | 1 | 2012 | 186 | 0.100 |
Why?
| Cross Infection | 1 | 2012 | 94 | 0.100 |
Why?
| Bacteremia | 1 | 2012 | 89 | 0.090 |
Why?
| Aged, 80 and over | 1 | 2018 | 3226 | 0.090 |
Why?
| Vascular Endothelial Growth Factor A | 1 | 2011 | 182 | 0.090 |
Why?
| Child | 2 | 2025 | 6906 | 0.090 |
Why?
| Proteomics | 1 | 2013 | 314 | 0.090 |
Why?
| Cytopathogenic Effect, Viral | 1 | 2010 | 5 | 0.090 |
Why?
| Colony-Forming Units Assay | 1 | 2010 | 25 | 0.090 |
Why?
| Basic-Leucine Zipper Transcription Factors | 1 | 2010 | 10 | 0.090 |
Why?
| China | 2 | 2025 | 90 | 0.090 |
Why?
| Reactive Nitrogen Species | 1 | 2010 | 23 | 0.090 |
Why?
| Cell Adhesion | 1 | 2010 | 157 | 0.080 |
Why?
| 3' Untranslated Regions | 1 | 2010 | 52 | 0.080 |
Why?
| Protein Isoforms | 1 | 2010 | 116 | 0.080 |
Why?
| Neoplasm Metastasis | 2 | 2020 | 232 | 0.080 |
Why?
| Neoplasm Staging | 1 | 2010 | 746 | 0.070 |
Why?
| Adolescent | 1 | 2018 | 6443 | 0.070 |
Why?
| Vero Cells | 1 | 2006 | 39 | 0.070 |
Why?
| Hemolysis | 1 | 2006 | 28 | 0.070 |
Why?
| Protein Structure, Secondary | 1 | 2006 | 71 | 0.070 |
Why?
| Sequence Homology, Amino Acid | 1 | 2006 | 144 | 0.070 |
Why?
| Protein Structure, Tertiary | 1 | 2006 | 245 | 0.060 |
Why?
| Binding Sites | 1 | 2006 | 362 | 0.060 |
Why?
| Zimbabwe | 1 | 2025 | 3 | 0.060 |
Why?
| Anti-Bacterial Agents | 2 | 2012 | 745 | 0.060 |
Why?
| Models, Molecular | 1 | 2006 | 334 | 0.060 |
Why?
| Molecular Sequence Data | 1 | 2006 | 778 | 0.060 |
Why?
| Receptors, Purinergic P2X7 | 1 | 2024 | 7 | 0.060 |
Why?
| Phosphatidylinositol 3-Kinases | 2 | 2017 | 140 | 0.060 |
Why?
| Models, Biological | 1 | 2006 | 716 | 0.050 |
Why?
| Feasibility Studies | 1 | 2025 | 390 | 0.050 |
Why?
| Receptors, Interleukin-1 | 1 | 2022 | 16 | 0.050 |
Why?
| Pilot Projects | 1 | 2025 | 698 | 0.050 |
Why?
| Adenosine Triphosphate | 1 | 2024 | 232 | 0.050 |
Why?
| Adaptive Immunity | 1 | 2022 | 32 | 0.050 |
Why?
| Sodium Chloride Symporters | 1 | 2022 | 7 | 0.050 |
Why?
| Kidney Tubules, Distal | 1 | 2022 | 14 | 0.050 |
Why?
| Mutation | 2 | 2020 | 1280 | 0.050 |
Why?
| Mice, Knockout | 1 | 2024 | 844 | 0.050 |
Why?
| Neovascularization, Physiologic | 1 | 2021 | 68 | 0.040 |
Why?
| Genome, Viral | 1 | 2020 | 79 | 0.040 |
Why?
| Proportional Hazards Models | 1 | 2021 | 415 | 0.040 |
Why?
| Phenotype | 2 | 2014 | 739 | 0.040 |
Why?
| Cross-Sectional Studies | 1 | 2025 | 1610 | 0.040 |
Why?
| Vimentin | 1 | 2019 | 32 | 0.040 |
Why?
| Cadherins | 1 | 2019 | 63 | 0.040 |
Why?
| CD4 Lymphocyte Count | 1 | 2018 | 32 | 0.040 |
Why?
| Bacterial Translocation | 1 | 2018 | 16 | 0.040 |
Why?
| Mice, Inbred C57BL | 1 | 2024 | 1808 | 0.040 |
Why?
| Promoter Regions, Genetic | 1 | 2020 | 465 | 0.040 |
Why?
| Oxygen | 1 | 2020 | 321 | 0.040 |
Why?
| Oncogene Protein v-akt | 1 | 2017 | 11 | 0.040 |
Why?
| TOR Serine-Threonine Kinases | 1 | 2017 | 78 | 0.030 |
Why?
| Niclosamide | 1 | 2015 | 1 | 0.030 |
Why?
| Parasitic Sensitivity Tests | 1 | 2015 | 2 | 0.030 |
Why?
| Acetylcholinesterase | 1 | 2015 | 18 | 0.030 |
Why?
| Esters | 1 | 2015 | 18 | 0.030 |
Why?
| L-Lactate Dehydrogenase | 1 | 2015 | 60 | 0.030 |
Why?
| Inhibitory Concentration 50 | 1 | 2015 | 69 | 0.030 |
Why?
| Nitric Oxide Synthase | 1 | 2015 | 74 | 0.030 |
Why?
| Zebrafish | 1 | 2015 | 55 | 0.030 |
Why?
| Case-Control Studies | 1 | 2018 | 1156 | 0.030 |
Why?
| Primary Cell Culture | 1 | 2014 | 60 | 0.030 |
Why?
| Monocarboxylic Acid Transporters | 1 | 2014 | 2 | 0.030 |
Why?
| Membrane Microdomains | 1 | 2014 | 12 | 0.030 |
Why?
| Vesicular Transport Proteins | 1 | 2014 | 36 | 0.030 |
Why?
| Gene Frequency | 1 | 2013 | 97 | 0.030 |
Why?
| Pedigree | 1 | 2013 | 119 | 0.030 |
Why?
| Molecular Typing | 1 | 2012 | 10 | 0.030 |
Why?
| DNA Mutational Analysis | 1 | 2013 | 175 | 0.030 |
Why?
| Molecular Epidemiology | 1 | 2012 | 36 | 0.030 |
Why?
| Alleles | 1 | 2013 | 256 | 0.030 |
Why?
| Skin Diseases | 1 | 2013 | 112 | 0.020 |
Why?
| Family | 1 | 2013 | 178 | 0.020 |
Why?
| Microbial Sensitivity Tests | 1 | 2012 | 269 | 0.020 |
Why?
| Genotype | 1 | 2012 | 533 | 0.020 |
Why?
| Enzyme Activation | 1 | 2011 | 268 | 0.020 |
Why?
| Hospitals | 1 | 2012 | 173 | 0.020 |
Why?
| Proto-Oncogene Proteins c-akt | 1 | 2011 | 156 | 0.020 |
Why?
| Follow-Up Studies | 1 | 2016 | 2242 | 0.020 |
Why?
| Genetic Predisposition to Disease | 1 | 2013 | 511 | 0.020 |
Why?
| Immunosorbent Techniques | 1 | 2008 | 5 | 0.020 |
Why?
| Antigen-Antibody Reactions | 1 | 2008 | 16 | 0.020 |
Why?
| Antibody Specificity | 1 | 2008 | 35 | 0.020 |
Why?
| Microspheres | 1 | 2008 | 27 | 0.020 |
Why?
| Epitopes | 1 | 2008 | 59 | 0.020 |
Why?
| Transplantation, Homologous | 1 | 2008 | 145 | 0.020 |
Why?
|
|
Qin's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|